Skip to contentpdufa.bio

surabgene lomparvovec (sura-vec, ABBV-RGX-314)

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

surabgene lomparvovec (sura-vec, ABBV-RGX-314) is a REGENXBIO Inc. program in wet AMD. Its next catalyst is a Readout in Q4 2026.

RGNX catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: Wet AMD. Sponsor: REGENXBIO Inc. (RGNX). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q4 2026RGNX

Specialist biotech funds holding RGNX, 13F for the quarter ended September 30, 2026

FundSharesValue at quarter endFiling
Redmile Group5,048,502$38.0 millionfiled November 16, 2026
RTW Investments555,555$4.2 millionfiled November 16, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is surabgene lomparvovec (sura-vec, ABBV-RGX-314)'s next FDA decision or readout?

The next tracked catalyst for surabgene lomparvovec (sura-vec, ABBV-RGX-314) is a Readout in Q4 2026.

What happened at surabgene lomparvovec (sura-vec, ABBV-RGX-314)'s most recent FDA decision?

No FDA decision for surabgene lomparvovec (sura-vec, ABBV-RGX-314) is in our archive yet.

What is surabgene lomparvovec (sura-vec, ABBV-RGX-314) used for?

In our records surabgene lomparvovec (sura-vec, ABBV-RGX-314) is under review or in development for Wet AMD.

Who makes surabgene lomparvovec (sura-vec, ABBV-RGX-314)?

REGENXBIO Inc. (RGNX).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.